Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LM11A 31 BHS

Next Previous
Search
Drug Profile

LM11A 31 BHS

Alternative Names: LM11A-31; LM11A-31-BHS

Latest Information Update: 23 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco; University of North Carolina at Chapel Hill
  • Developer PharmatrophiX
  • Class Antidementias; Neuroprotectants; Small molecules
  • Mechanism of Action Nerve growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 17 May 2024 Adverse events data from a phase II trial in Alzheimer's Disease released by PharmatrophiX
  • 28 Sep 2022 Phase-II development is ongoing in Austria, Czech Republic, Germany, Spain and Sweden (PO) (Pharmatrophix website, September 2022)
  • 03 Aug 2022 Pharmacodynamics data from a phase II trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top